Literature DB >> 10681359

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

W R Kirkpatrick1, R K McAtee, A W Fothergill, D Loebenberg, M G Rinaldi, T F Patterson.   

Abstract

SCH56592 (SCH) was evaluated in an immunosuppressed rabbit model of invasive aspergillosis. SCH was more effective than similar doses of itraconazole and as effective as amphotericin B in the clearance of Aspergillus spp. from tissues. Compared with controls, SCH regimens reduced mortality, improved survival, and significantly reduced tissue colony counts.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10681359      PMCID： PMC89767          DOI： 10.1128/AAC.44.3.780-782.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model.

Authors:  T F Patterson; P Miniter; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

2.  In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors:  K L Oakley; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 4.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

Authors:  D W Denning; S A Radford; K L Oakley; L Hall; E M Johnson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

Review 6.  New antifungal agents.

Authors:  J R Graybill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

7.  Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.

Authors:  T F Patterson; D George; R Ingersoll; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

8.  Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.

Authors:  J R Graybill; S R Kaster
Journal:  Am Rev Respir Dis       Date:  1984-02

9.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

10.  Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.

Authors:  T F Patterson; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191
View more
  16 in total

1.  Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.

Authors:  William R Kirkpatrick; Ana C Vallor; Robert K McAtee; Neil S Ryder; Annette W Fothergill; Michael G Rinaldi; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles.

Authors:  Elizabeth R Ramos; Ying Jiang; Ray Hachem; Christelle Kassis; Dimitrios P Kontoyiannis; Issam Raad
Journal:  Oncologist       Date:  2011-06-09

3.  Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Authors:  Alexander J Lepak; Karen Marchillo; Jaimie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 4.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

5.  In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors:  A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 8.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits.

Authors:  Javier Capilla; Clara Yustes; Emili Mayayo; Belkys Fernández; Montserrat Ortoneda; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.

Authors:  Abdullah Ayçiçek; Zafer Cetinkaya; Halil Kiyici; Fethullah Kenar; Gülşah Aşik; Nuri Kiraz
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-04-02       Impact factor: 2.503
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.